Trajectories of humoral and cellular immunity and responses to a third dose of mRNA vaccines against SARS-CoV-2 in patients with a history of anti-CD20 therapy.
COVID-19
rituximab
systemic vasculitis
vaccination
Journal
RMD open
ISSN: 2056-5933
Titre abrégé: RMD Open
Pays: England
ID NLM: 101662038
Informations de publication
Date de publication:
03 2022
03 2022
Historique:
received:
17
12
2021
accepted:
09
03
2022
entrez:
1
4
2022
pubmed:
2
4
2022
medline:
5
4
2022
Statut:
ppublish
Résumé
The majority of patients with B-cell-depleting therapies show compromised vaccination-induced immune responses. Herein, we report on the trajectories of anti-SARS-CoV-2 immune responses in patients of the RituxiVac study compared with healthy volunteers and investigate the immunogenicity of a third vaccination in previously humoral non-responding patients. We investigated the humoral and cell-mediated immune response after SARS-CoV-2 messanger RNA vaccination in patients with a history with anti-CD20 therapies. Coprimary outcomes were antispike and SARS-CoV-2-stimulated interferon-γ concentrations in vaccine responders 4.3 months (median; IQR: 3.6-4.8 months) after first evaluation, and humoral and cell-mediated immunity (CMI) after a third vaccine dose in previous humoral non-responders. Immunity decay rates were compared using analysis of covariance in linear regression. 5.6 months (IQR: 5.1-6.7) after the second vaccination, we detected antispike IgG in 88% (29/33) and CMI in 44% (14/32) of patients with a humoral response after two-dose vaccination compared with 92% (24/26) healthy volunteers with antispike IgG and 69% (11/16) with CMI 6.8 months after the second vaccination (IQR: 6.0-7.1). Decay rates of antibody concentrations were comparable between patients and controls (p=0.70). In two-dose non-responders, a third SARS-CoV-2 vaccine elicited humoral responses in 19% (6/32) and CMI in 32% (10/31) participants. This study reveals comparable immunity decay rates between patients with anti-CD20 treatments and healthy volunteers, but inefficient humoral or CMI after a third SARS-CoV-2 vaccine in most two-dose humoral non-responders calling for individually tailored vaccination strategies in this population.Trial registration numberNCT04877496; ClinicalTrials.gov number.
Sections du résumé
BACKGROUND
The majority of patients with B-cell-depleting therapies show compromised vaccination-induced immune responses. Herein, we report on the trajectories of anti-SARS-CoV-2 immune responses in patients of the RituxiVac study compared with healthy volunteers and investigate the immunogenicity of a third vaccination in previously humoral non-responding patients.
METHODS
We investigated the humoral and cell-mediated immune response after SARS-CoV-2 messanger RNA vaccination in patients with a history with anti-CD20 therapies. Coprimary outcomes were antispike and SARS-CoV-2-stimulated interferon-γ concentrations in vaccine responders 4.3 months (median; IQR: 3.6-4.8 months) after first evaluation, and humoral and cell-mediated immunity (CMI) after a third vaccine dose in previous humoral non-responders. Immunity decay rates were compared using analysis of covariance in linear regression.
RESULTS
5.6 months (IQR: 5.1-6.7) after the second vaccination, we detected antispike IgG in 88% (29/33) and CMI in 44% (14/32) of patients with a humoral response after two-dose vaccination compared with 92% (24/26) healthy volunteers with antispike IgG and 69% (11/16) with CMI 6.8 months after the second vaccination (IQR: 6.0-7.1). Decay rates of antibody concentrations were comparable between patients and controls (p=0.70). In two-dose non-responders, a third SARS-CoV-2 vaccine elicited humoral responses in 19% (6/32) and CMI in 32% (10/31) participants.
CONCLUSION
This study reveals comparable immunity decay rates between patients with anti-CD20 treatments and healthy volunteers, but inefficient humoral or CMI after a third SARS-CoV-2 vaccine in most two-dose humoral non-responders calling for individually tailored vaccination strategies in this population.Trial registration numberNCT04877496; ClinicalTrials.gov number.
Identifiants
pubmed: 35361691
pii: rmdopen-2021-002166
doi: 10.1136/rmdopen-2021-002166
pmc: PMC8971359
pii:
doi:
Substances chimiques
Antibodies, Viral
0
COVID-19 Vaccines
0
Vaccines, Synthetic
0
Viral Vaccines
0
mRNA Vaccines
0
Banques de données
ClinicalTrials.gov
['NCT04877496']
Types de publication
Clinical Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
N Engl J Med. 2021 Dec 9;385(24):e85
pubmed: 34706170
Clin Chem Lab Med. 2020 Oct 25;58(11):e251-e253
pubmed: 32692698
N Engl J Med. 2021 Sep 23;385(13):1244-1246
pubmed: 34379917
Ann Rheum Dis. 2022 Jan 12;:
pubmed: 35022159
Kidney Int. 2021 Nov;100(5):1124-1127
pubmed: 34499910
Lancet Rheumatol. 2022 Jan;4(1):e13-e16
pubmed: 34778844
Ann Rheum Dis. 2021 Oct;80(10):1330-1338
pubmed: 34127481
N Engl J Med. 2021 Jun 10;384(23):2259-2261
pubmed: 33822494
Lancet Rheumatol. 2021 Nov;3(11):e789-e797
pubmed: 34514436
Lancet Reg Health Eur. 2021 Nov;10:100208
pubmed: 34514454
Clin Infect Dis. 2021 Dec 6;73(11):2145-2147
pubmed: 33825869
Cancer Cell. 2022 Feb 15;:
pubmed: 35172125
Transplantation. 2021 Dec 1;105(12):e280-e281
pubmed: 34428188
Arthritis Rheumatol. 2021 Dec 28;:
pubmed: 34962357
Sci Rep. 2021 Aug 18;11(1):16796
pubmed: 34408200
Ann Rheum Dis. 2022 Jan 13;:
pubmed: 35027397
Nature. 2022 Feb 15;:
pubmed: 35168246
Ann Rheum Dis. 2021 Nov 24;:
pubmed: 34819271
Ann Intern Med. 2021 Nov;174(11):1572-1585
pubmed: 34461029
Clin Microbiol Infect. 2020 Oct;26(10):1386-1394
pubmed: 32603801
PLoS Negl Trop Dis. 2021 Jul 8;15(7):e0009551
pubmed: 34237072
N Engl J Med. 2021 Aug 12;385(7):661-662
pubmed: 34161700
J Med Econ. 2021 Jan-Dec;24(1):1248-1260
pubmed: 34844493
Nat Med. 2021 Nov;27(11):1990-2001
pubmed: 34522051
Vaccines (Basel). 2021 Dec 11;9(12):
pubmed: 34960216
RMD Open. 2022 Feb;8(1):
pubmed: 35115385
Allergy. 2021 Mar;76(3):853-865
pubmed: 32997812
Sci Immunol. 2020 Oct 8;5(52):
pubmed: 33033172
Lancet Rheumatol. 2022 Mar;4(3):e177-e187
pubmed: 34977602